Drug Trial News

RSS

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

5 Jul 2023

SYS6006 investigational COVID-19 mRNA vaccine shows promise as fourth dose booster

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 600 million confirmed cases and 6.5 million deaths worldwide.

4 Jul 2023

PSI-developed drug could increase survival chances for metastatic prostate cancer patients

Researchers at PSI have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer.

4 Jul 2023

Growth factor study reveals potential breakthrough in obesity management

Study discusses the effects of a growth factor that showed promising results in mice in an obesity trial.

4 Jul 2023

Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

Researchers performed a double-blinded, placebo-controlled phase III randomized clinical trial (RCT).

29 Jun 2023

The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

Researchers performed a phase II randomized clinical trial (RCT).

29 Jun 2023

Study reveals oral Semaglutide 50 mg as promising treatment for obesity in adults: the Lancet report

Researchers performed a phase III randomized clinical trial (RCT).

29 Jun 2023

Trial shows no benefit of prescribing an opioid for people with acute back or neck pain

Opioid pain-relieving medicines are not more effective than a placebo in relieving acute back and neck pain and may even cause harm, according to a world-first trial led by the University of Sydney.

28 Jun 2023

New drug effective as a treatment against ulcerative colitis, clinical trial shows

A new drug, investigated by Amsterdam UMC together with colleagues around the world, is effective as a treatment against ulcerative colitis.

28 Jun 2023

New hope for cystic fibrosis patients as groundbreaking treatment enters clinical trial

Clinical testing is underway for a potentially groundbreaking new treatment for cystic fibrosis. Pioneered by scientists at Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign and the Carver College of Medicine at the University of Iowa in partnership with the spin-out biotechnology company, cystetic Medicines, this promising inhalable molecular prosthetic is intended to improve lung function in people with CF who cannot benefit from current therapies.

26 Jun 2023

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

22 Jun 2023

Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke?

Researchers examined the effectiveness and safety of using Panax notoginseng saponins for ischemic stroke in adults.

22 Jun 2023

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

20 Jun 2023

Adagrasib shows promise for the treatment of patients with KRAS G12C-mutated non-small cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer.

16 Jun 2023

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Researchers performed a double-blinded, phase III randomized trial.

15 Jun 2023

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial funded by the National Eye Institute.

13 Jun 2023

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

In a recent article published in the journal JAMA Network, researchers performed a randomized clinical trial (RCT) to demonstrate the noninferiority of letermovir vs. valganciclovir for prophylaxis of cytomegalovirus (CMV) in adult CMV-seronegative kidney transplant recipients (KTRs) who received a kidney from a CMV-seropositive individual.

13 Jun 2023

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.

12 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Researchers in the Hermelin Brain Tumor Center at Henry Ford Health are leading a Phase I clinical trial studying the maximum tolerated dose of an oncolytic adenovirus, a mutated virus engineered to selectively replicate in and destroy cancer tissue, in combination with fractionated stereotactic radiosurgery among patients who are undergoing resection of a recurrent high-grade astrocytoma brain tumor.

8 Jun 2023

Previous
1
...
17
18
19
20
21
22
23
...
1143
Next

Drug Trial News

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

SYS6006 investigational COVID-19 mRNA vaccine shows promise as fourth dose booster

PSI-developed drug could increase survival chances for metastatic prostate cancer patients

Growth factor study reveals potential breakthrough in obesity management

Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

Study reveals oral Semaglutide 50 mg as promising treatment for obesity in adults: the Lancet report

Trial shows no benefit of prescribing an opioid for people with acute back or neck pain

New drug effective as a treatment against ulcerative colitis, clinical trial shows

New hope for cystic fibrosis patients as groundbreaking treatment enters clinical trial

First successful Phase 2 trial uses cutting-edge RNA CAR-T therapy to treat autoimmunity

Do Panax notoginseng saponins (Xuesaitong soft capsules) improve function in patients with ischemic stroke?

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

Adagrasib shows promise for the treatment of patients with KRAS G12C-mutated non-small cell lung cancer

Phase 3 clinical trial shows favorable safety and immunogenicity profile of single-shot live-attenuated chikungunya vaccine

Repeat intraocular corticosteroid injections improve vision in people with persistent or recurrent uveitic macular edema

Letermovir: A promising breakthrough in CMV prevention for kidney transplant recipients

VLA1553 vaccine candidate for chikungunya disease produces an immune response in a phase 3 trial

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Study may help advance data on oncolytic adenovirus mediated double suicide-gene therapy for high-grade brain tumors

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News